# 阿斯利康表示，美國食品藥物管理局推遲了是否批准一款新乳癌藥物的決定。

*biotech · news · 2026-05-27 · MarketScreener*

## Key points

- FDA延後對阿斯利康乳癌藥物camizestrant的決定，以審查新數據。
- 阿斯利康提交了包括camizestrant長期療效結果在內的額外分析資料。
- camizestrant上個月曾遭FDA諮詢委員會投下反對票。
- 歐洲藥品管理局委員會上週五對camizestrant發表正面意見。

By Adria Calatayud AstraZeneca said the U.S. Food and Drug Administration is pushing back its decision on whether to approve a new breast-cancer drug in order to review additional data provided by the company. The U.K. drugmaker said Wednesday that it provided additional analyses requested by the FDA in support of its application for the drug candidate, camizestrant, after the regulator's drugs advisory committee voted against its approval late last month. The new information provided by the company included data linked to longer-term efficacy outcomes that will be presented at a medical conference next week, AstraZeneca said. The European Medicines Agency said Friday that its committee for medicinal products for human use issued a positive opinion on camizestrant. Write to Adria Calatayud at adria.calatayud@wsj.com (END) Dow Jones Newswires 05-27-26 0237ET

**Companies:** AstraZeneca
**Countries:** United States, United Kingdom

[Read the full story on MarketScreener](https://www.marketscreener.com/news/astrazeneca-gets-fda-review-extension-for-breast-cancer-drug-ce7f5ad2de8bfe24)

---

Canonical: https://newsio.io/zh-TW/n/a7ce8247-afc9-4549-b0cb-fd9efd6fb14d/fda
Summarized by Newsio from MarketScreener. https://newsio.io/how-it-works